Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $233.47 (market cap $11.14B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.71. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| CRL | VNQI | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $50.76 |
52-Week Low | $145.57 | $43.26 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.11, down 0.94% with bearish technical signals from moving averages. The ETF provides international real estate diversification with 682 holdings across 30+ countries, featuring a 0.12% expense ratio and 4.6% dividend yield. Recent analysis highlights its cost advantage over competitors but notes underperformance in total returns compared to domestic REIT ETFs over the past five years.
The outlook remains cautious due to technical weakness and mixed performance history. Investment opportunity lies in global diversification and attractive yield, though risks include currency exposure and slower international real estate recovery. Analyst sentiment is neutral with recovery potential noted as global transaction volumes are expected to increase over 10% in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
